Nxera Pharma says Neurocrine wins FDA IND clearance for Phase 2 Alzheimer’s cognition trial of NBI-1117567

Reuters2026/08/26 07:33

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Neurocrine received FDA IND acceptance for a Phase 2 study of NBI-1117567 targeting cognition in Alzheimer’s disease in Q3 FY2026.
No trial results were presented; the update relates to the start of a mid-stage clinical program.
Nxera will receive a USD 10 million milestone payment, expected to be recognized as revenue in Q3 FY2026.
The drug is an oral, muscarinic M1-preferring agonist discovered by Nxera, developed under a multi-program collaboration with Neurocrine.
Nxera retains development and commercialization rights for the M1 receptor agonist in Japan across all indications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nxera Pharma Co. Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608260333PRIMZONEFULLFEED1001259394) on August 26, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Nxera Pharma says Neurocrine wins FDA IND clearance for Phase 2 Alzheimer’s cognition trial of NBI-1117567

You may also like

Crypto prices